INCYTE CORP Company Profile
✉ Email this page to a colleague
What is the competitive landscape for INCYTE CORP, and what generic alternatives to INCYTE CORP drugs are available?
INCYTE CORP has three approved drugs.
There are twenty-four US patents protecting INCYTE CORP drugs.
There are three hundred and ninety-six patent family members on INCYTE CORP drugs in fifty countries and forty-one supplementary protection certificates in eighteen countries.
Drugs and US Patents for INCYTE CORP
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-002 | Nov 16, 2011 | RX | Yes | No | 10,016,429*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | 10,869,870*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Incyte Corp | JAKAFI | ruxolitinib phosphate | TABLET;ORAL | 202192-005 | Nov 16, 2011 | RX | Yes | Yes | 9,079,912*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Incyte Corp | OPZELURA | ruxolitinib phosphate | CREAM;TOPICAL | 215309-001 | Sep 21, 2021 | RX | Yes | Yes | 8,822,481*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Incyte Corp | PEMAZYRE | pemigatinib | TABLET;ORAL | 213736-001 | Apr 17, 2020 | RX | Yes | No | 9,611,267 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for INCYTE CORP drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Tablets | 5 mg, 10 mg, 15 mg, 20 mg, and 25 mg | ➤ Subscribe | 2015-12-17 |
International Patents for INCYTE CORP Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Costa Rica | 10065 | ⤷ Try a Trial |
Japan | 2021523121 | ⤷ Try a Trial |
Georgia, Republic of | P20125533 | ⤷ Try a Trial |
Cyprus | 1118607 | ⤷ Try a Trial |
Montenegro | 02651 | ⤷ Try a Trial |
Hungary | E032337 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for INCYTE CORP Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1966202 | SPC/GB13/005 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: RUXOLITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/12/773/001 20120828; UK EU/1/12/773/002 20120828; UK EU/1/12/773/003 20120828 |
2455382 | 122017000020 | Germany | ⤷ Try a Trial | PRODUCT NAME: RUXOLITINIB, ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/773/001-003 20150311 |
1966202 | C01966202/01 | Switzerland | ⤷ Try a Trial | FORMER OWNER: INCYTE CORPORATION, US |
2861595 | PA2021519,C2861595 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: PEMIGATINIBAS ARBA JO FARMACISKAI PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/21/1535 20210326 |
1966202 | 1390005-5 | Sweden | ⤷ Try a Trial | PRODUCT NAME: RUXOLITINIB, ELLER ETT FARMACEUTISKT GODTAGBART SALT DAERAV; REG. NO/DATE: EU/1/12/773/001; 2012-08-23; PERIOD OF VALIDITY (FROM - UNTIL): 2026-12-13 - 2027-08-27 |
2861595 | 2021C/536 | Belgium | ⤷ Try a Trial | PRODUCT NAME: PEMIGATINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/21/1535 20210329 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.